NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Neumora Therapeutics, Inc. (NMRA)
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company’s Offering Documents in connection with its initial public offering (“IPO”) conducted on September 15, 2023, are encouraged to contact the firm before April 7, 2025.If you are a shareholder who suffered a loss, click here to participate.We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.The class, in this case, has not yet been certified, and until certification occurs, you are not repres
Show less
Read more
Impact Snapshot
Event Time:
NMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NMRA alerts
High impacting Neumora Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NMRA
News
- Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating.MarketBeat
- Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Stifel Nicolaus from $2.00 to $3.00. They now have a "hold" rating on the stock.MarketBeat
- Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02 [Seeking Alpha]Seeking Alpha
- Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Neumora Therapeutics to Participate in Upcoming Conferences in NovemberGlobeNewswire
NMRA
Earnings
- 11/6/25 - Miss
NMRA
Sec Filings
- 11/21/25 - Form 8-K
- 11/12/25 - Form 144
- 11/6/25 - Form 10-Q
- NMRA's page on the SEC website